AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

140.2 USD

Average target price

161.5 USD

Spread / Average Target

+15.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+7.09%	217B
ELI LILLY AND COMPANY	+26.16%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.22%	360B
MERCK & CO., INC.	+16.67%	321B
ABBVIE INC.	+8.62%	300B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.65%	149B
AMGEN INC.	-4.62%	147B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:03 2024-04-24 am EDT			5-day change	1st Jan Change
11,352 ^GBX	+0.75%		+4.51%	+7.09%

06:08pm	No record close for FTSE 100; mixed trade in US	AN
06:02pm	No record close for FTSE 100; mixed trade in US	AN

No record close for FTSE 100; mixed trade in US	12:08pm	AN
No record close for FTSE 100; mixed trade in US	12:02pm	AN
Angle plc to Develop New Cancer Assay in Deal with AstraZeneca	10:14am	MT
ASTRAZENECA : Bernstein reiterates its Buy rating	07:38am	ZD
Angle shares jump on supplier agreement with with AstraZeneca	05:34am	AN
AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook	05:12am	AN
Angle PLC Announces New Commercial Agreement with AstraZeneca PLC	02:00am	CI
AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	Apr. 23	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Apr. 23	ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN	Apr. 23	CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Market sentiment sours	Apr. 16
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	Apr. 16	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
AstraZeneca: improvements in biliary tract cancer	Apr. 16	CF
AstraZeneca's hails Imfinzi survival data on cancer form	Apr. 16	AN